{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Data presented at AASLD 2022.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/16",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.23,
        "x": 0.27,
        "y": 0.27
      },
      "kind": "list",
      "text": "Discontinuation of both AB-729 and NA-therapy results in a sustained reduction in HBsAg. No evidence of virologic or biochemical relapse detected in 9 patients who discontinued all therapy from 12 to 44 weeks.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14b6f068-4201-457f-b16f-fd7d76baf6e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.21,
        "x": 0.76,
        "y": 0.27
      },
      "kind": "list",
      "text": "AB-729 was generally safe and well-tolerated after completing dosing in 41 patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3352c0ad-ded8-4749-ae5e-52545c27ebef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.23,
        "x": 0.025,
        "y": 0.27
      },
      "kind": "list",
      "text": "AB-729 provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status. ~75% (26 of 34) patients had HBsAg levels <100 at some point. 50% (16 of 32) maintained HBsAg <100 IU/mL for 24 weeks after stopping.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfb7908b-bd11-4248-aba4-394aa458c7d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.23,
        "x": 0.515,
        "y": 0.27
      },
      "kind": "list",
      "text": "AB-729 continues to result in HBV-specific T-cell immune restoration and decrease of exhausted T-cells.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef650110-cfb2-48c4-ab77-e77d3609432d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.15,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "* Data presented at AASLD 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aee34846-1a79-495e-92a1-ad1fde1df984",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.075,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-729-001 Clinical Trial Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2a3769a-aaa8-458e-9248-9fc551d37449",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a326158e-ef83-481a-a7e2-05759d5caa8d",
      "evidence": "list/bullet: AB-729 provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status. ~75% (26 of 34) patients had HBsAg levels <100 at some point. 50% (16 of 32) maintained HBsAg <1",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}